Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional demand....
Los Angeles , June 11, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A....
NEW YORK , June 9, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ABIVAX Societe Anonyme (NASDAQ: ABVX).
LOS ANGELES , June 8, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A....
New York, New York--(Newsfile Corp. - June 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into ABIVAX Societe Anonyme ("ABIVAX Societe Anonyme") (NASDAQ: ABVX) concerning...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ:...
Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of their...
In a report released on October 6, Thomas Smith from Leerink Partners reiterated a Buy rating on Abivax SA Sponsored ADR. The company’s shares closed yesterday at $87.01.Elevate Your Investing Strategy:...
Kepler Capital analyst Justine Telliez maintained a Buy rating on Abivax SA on October 6 and set a price target of €70.00. The company’s shares closed yesterday at €73.50.Elevate Your Investing Strategy:...
Shares of Abivax SA (NASDAQ: ABVX) went parabolic on Wednesday, skyrocketing 586% to close at $68.60 after the French biotech firm announced overwhelmingly positive Phase 3 data for its lead drug candidate,...